184 related articles for article (PubMed ID: 17699373)
1. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
Zager RA
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S24-31. PubMed ID: 17699373
[TBL] [Abstract][Full Text] [Related]
2. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
3. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
4. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.
Zager RA; Johnson AC; Hanson SY; Wasse H
Am J Kidney Dis; 2002 Jul; 40(1):90-103. PubMed ID: 12087566
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
6. Intravenous iron therapy in non-dialysis CKD patients.
Macdougall IC
Nephrol Dial Transplant; 2014 Apr; 29(4):717-20. PubMed ID: 24319013
[No Abstract] [Full Text] [Related]
7. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release.
Zager RA; Johnson AC; Hanson SY; Lund S
Am J Physiol Renal Physiol; 2005 Feb; 288(2):F290-7. PubMed ID: 15494544
[TBL] [Abstract][Full Text] [Related]
8. More than a decade of experience and still no consensus: controversies in iron therapy.
Besarab A
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S1-3. PubMed ID: 17699371
[No Abstract] [Full Text] [Related]
9. Iron Treatment Strategies in Nondialysis CKD.
Macdougall IC
Semin Nephrol; 2016 Mar; 36(2):99-104. PubMed ID: 27236130
[TBL] [Abstract][Full Text] [Related]
10. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
11. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
12. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Potthoff SA; Münch HG
Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
14. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
Rottembourg J; Rostoker G
Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
[TBL] [Abstract][Full Text] [Related]
15. Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine.
Muntané J; Puig-Parellada P; Mitjavila MT
J Lab Clin Med; 1995 Nov; 126(5):435-43. PubMed ID: 7595028
[TBL] [Abstract][Full Text] [Related]
16. Safety Issues in Iron Treatment in CKD.
Vaziri ND
Semin Nephrol; 2016 Mar; 36(2):112-8. PubMed ID: 27236132
[TBL] [Abstract][Full Text] [Related]
17. The Use of Parenteral Iron Therapy for the Treatment of Postpartum Anemia.
Nash CM; Allen VM
J Obstet Gynaecol Can; 2015 May; 37(5):439-442. PubMed ID: 26168105
[TBL] [Abstract][Full Text] [Related]
18. Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.
Fishbane S
Semin Nephrol; 2016 Mar; 36(2):119-23. PubMed ID: 27236133
[TBL] [Abstract][Full Text] [Related]
19. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
20. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
Zager RA
Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
